Eli Lilly warms up for summer launch with long-term success goal

US-based Eli Lilly is expecting to launch type 2 diabetes treatment tirzepatide this summer without intending to disrupt the market. According to the company, it’s all about ensuring success on the long term, which could be good news for competitor Novo Nordisk.


Eli Lilly is making explicit comments to the market that could be positively interpreted for competitor Novo Nordisk.

In summer, when the US-based company launches diabetes drug tirzepatide, the plan isn’t to send shock waves through the market. The drug is in direct competition with Novo Nordisk’s best-seller Ozempic.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs